Chemotherapy-free strategies in treating leukaemia

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy

Multiple myeloma science from EHA 2019

CAR T-cell therapy for treating acute leukaemia

Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM

ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone

PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma

HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

Chemoimmunotherapy or BTK inhibition for patients with CLL

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Blinatumomab for relapsed/refractory Burkitt's lymphoma

Using bioinformatics and genomics to treat AML

The changing landscape of AML

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

RESONATE-2: Five-year follow up of CLL patients receiving ibrutinib as first-line treatment

CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML

Targeted treatment of AML using T cell recruiting antibody constructs

Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma

Myeloma highlights from EHA 2019

Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia

Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities

AlloHCT conditioning intensity in AML in complete remission with residual disease

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL

Inhibition of NADK strongly inhibits T-ALL cells from growing

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia

Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM

Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety

Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities

Intervention for AML patients with MRD can result in improved survival